Factors associated with subclinical atherosclerosis in HIV infected patients from northeast of Brazil
DOI:
https://doi.org/10.33448/rsd-v10i12.20484Keywords:
HIV; AIDS; Cardiovascular risk factors; Coronary Calcium Score; Coronary calcification.Abstract
Introduction: AIDS has changed its morbidity curve, rising cardiovascular diseases. HIV-infected patients have increased cardiovascular event rates but data on the prevalence of subclinical atherosclerosis are not uniform. Methods: HIV-infected patients underwent to coronary tomography for CACs assessement. We performed a comparison between 97 HIV-infected patients and 129 seronegative healthy controls. The univariable analysis matched the association of HIV infection, cardiovascular risk profile, and HIV-related factors with subclinical atherosclerosis. Results: HIV-infected patients with CACs above zero were older (54.8±7.0 vs. 43.3.5±11.0 years; p<0.001) and more likely to have hypertension (36.7% vs. 12.5%; p=0.07) than HIV(-) CACs zero ones. Factors associated with altered CACs in unadjusted hazard ratio were age (HR=1.13; 95%CI=1.07-1.20; p<0.0001) and hypertension (HR=4.05; 95%CI=1.42-11.60; p=0.0009). When adjusted hazard ratio was constructed age, male gender and protease inhibitors (PI) use appeared as factors associated with coronary calcification. HIV-infected patients were less likely to have hypertension (20.2% vs 50.4%; p<0.001) and diabetes (5.3% vs 23.3%; p<0.001) than HIV uninfected ones. Conversely, both groups have same CACs level. Among HIV-infected patients altered CACs was 30.9%, vs 42.3% among control. Most of HIV-infected patients showed undetectable viremia and high CD4+ count, in parallel with lipid profile disturbances. Conclusion: Increased CAC incidence was associated with age, male gender and PI use among HIV-infected patients. Despite younger, fewer traditional risk factors and with controlled disease, the PLHIV had similar CAC scores compared with controls. Besides viruses itself, antiretroviral drugs play a role, mainly because control viruses at expense of worsening in lipid profile.
References
Agatston, A. S., Janowitz, W. R., Hildner, F. J., Zusmer, N. R., Viamonte, M., & Detrano, R. (1990). Quantification of coronary artery calcium using ultrafast computed tomography. Journal of the American College of Cardiology, 15(4), 827-832.
Almeida-Brasil, C. C., Nascimento, E. D., Silveira, M. R., Bonolo, P. D. F., & Ceccato, M. D. G. B. (2019). New patient-reported outcome measure to assess perceived barriers to antiretroviral therapy adherence: the PEDIA scale. Cadernos de saude publica, 35.
Chandra, D., Gupta, A., Fitzpatrick, M., Haberlen, S. A., Neupane, M., Leader, J. K., Kingsley, L. A., Kleerup, E., Budoff, M. J., Witt, M., Sciurba, F. C., Post, W. S., & Morris, A. (2019). Lung Function, Coronary Artery Disease, and Mortality in HIV. Annals of the American Thoracic Society, 16(6), 687–697.
Erbel, R., Möhlenkamp, S., Moebus, S., Schmermund, A., Lehmann, N., Stang, A., ... & Heinz Nixdorf Recall Study Investigative Group. (2010). Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. Journal of the American College of Cardiology, 56(17), 1397-1406.
Freiberg, M. S., Chang, C. C. H., Kuller, L. H., Skanderson, M., Lowy, E., Kraemer, K. L., ... & Justice, A. C. (2013). HIV infection and the risk of acute myocardial infarction. JAMA internal medicine, 173(8), 614-622.
Freiberg, M. S., Chang, C. H., Kuller, L. H., Goetz, M. B., Leaf, D., & Oursler, K. A. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med [Internet]. 2013; 173 (8): 614–22.
Friis-Møller, N., Ryom, L., Smith, C., Weber, R., Reiss, P., Dabis, F., ... & Law, M. (2016). An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D: A: D) study. European journal of preventive cardiology, 23(2), 214-223.
Ghislain, M., Bastard, J. P., Meyer, L., Capeau, J., Fellahi, S., Gérard, L., ... & ANRS-COPANA Cohort Study Group. (2015). Late antiretroviral therapy (ART) initiation is associated with long-term persistence of systemic inflammation and metabolic abnormalities. PLoS One, 10(12), e0144317.
Gilbert, J. M., Fitch, K. V., & Grinspoon, S. K. (2015). HIV-related cardiovascular disease, statins, and the REPRIEVE trial. Topics in antiviral medicine, 23(4), 146.
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., ... & Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 73(24), e285-e350.
Gutierrez, J., Albuquerque, A. L. A., & Falzon, L. (2017). HIV infection as vascular risk: a systematic review of the literature and meta-analysis. PloS one, 12(5), e0176686.
Ingle, S. M., May, M. T., Gill, M. J., Mugavero, M. J., Lewden, C., Abgrall, S., ... & Antiretroviral Therapy Cohort Collaboration. (2014). Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clinical Infectious Diseases, 59(2), 287-297.
Julius, H., Basu, D., Ricci, E., Wing, J., Kusari Basu, J., Pocaterra, D., & Bonfanti, P. (2011). The burden of metabolic diseases amongst HIV positive patients on HAART attending The Johannesburg Hospital. Current HIV research, 9(4), 247-252.
Kearns, A., Gordon, J., Burdo, T. H., & Qin, X. (2017). HIV-1–associated atherosclerosis: unraveling the missing link. Journal of the American College of Cardiology, 69(25), 3084-3098.
Kingsley, L. A., Jennifer, D. E. A. L., Jacobson, L., Budoff, M., Mallory, W. I. T. T., Palella, F., & Calhoun, B. (2015). Incidence and progression of coronary artery calcium (CAC) in HIV-infected and HIV-uninfected men. AIDS (London, England), 29(18), 2427.
Lang, S., Boccara, F., Mary-Krause, M., & Cohen, A. (2015). Epidemiology of coronary heart disease in HIV-infected versus uninfected individuals in developed countries. Archives of cardiovascular diseases, 108(3), 206-215.
Lewden, C., Chêne, G., Morlat, P., Raffi, F., Dupon, M., Dellamonica, P., ... & Leport, C. (2007). HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. JAIDS Journal of Acquired Immune Deficiency Syndromes, 46(1), 72-77.
Lo, J., Abbara, S., Shturman, L., Soni, A., Wei, J., Rocha-Filho, J. A., ... & Grinspoon, S. K. (2010). Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS (London, England), 24(2), 243.
Lo, J., Looby, S. E. D., Wei, J., Adler, G. K., & Grinspoon, S. K. (2009). Increased aldosterone among HIV-infected women with visceral fat accumulation. AIDS (London, England), 23(17), 2366.
Lundgren, J. D., Babiker, A. G., Gordin, F., Emery, S., Grund, B., Sharma, S., ... & Neaton, J. D. (2015). Initiation of antiretroviral therapy in early asymptomatic HIV infection. The New England journal of medicine, 373(9), 795-807.
Mooney, S., Tracy, R., Osler, T., & Grace, C. (2015). Elevated biomarkers of inflammation and coagulation in patients with HIV are associated with higher Framingham and VACS risk index scores. PloS one, 10(12), e0144312.
Nadel, J., & Holloway, C. J. (2017). Screening and risk assessment for coronary artery disease in HIV infection: an unmet need. HIV medicine, 18(4), 292-299.
Patel, A. A., & Budoff, M. J. (2021). Coronary artery disease in patients with HIV infection: an update. American Journal of Cardiovascular Drugs, 21(4), 411-417
Sara L, Szarf G, Tachibana A, Shiozaki AA, Villa AV, Oliveira AC et al. Sociedade Brasileira de Cardiologia. II Diretriz de Ressonância Magnética e Tomografia Computadorizada Cardiovascular da Sociedade Brasileira de Cardiologia e do Colégio Brasileiro de Radiologia. Arq Bras Cardiol 2014; 103(6Supl.3): 1-86
Senoner, T., Barbieri, F., Adukauskaite, A., Sarcletti, M., Plank, F., Beyer, C., ... & Feuchtner, G. M. (2019). Coronary atherosclerosis characteristics in HIV-infected patients on long-term antiretroviral therapy: insights from coronary computed tomography–angiography. Aids, 33(12), 1853-1862.
Sinha, A., & Feinstein, M. J. (2019). Coronary artery disease manifestations in HIV: what, how, and why. Canadian Journal of Cardiology, 35(3), 270-279.
Triant, V. A., Lee, H., Hadigan, C., & Grinspoon, S. K. (2007). Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. The Journal of Clinical Endocrinology & Metabolism, 92(7), 2506-2512.
Vachiat, A., McCutcheon, K., Tsabedze, N., Zachariah, D., & Manga, P. (2017). HIV and ischemic heart disease. Journal of the American College of Cardiology, 69(1), 73-82.
Vilela, F. D., Lorenzo, A. R. D., Tura, B. R., Ferraiuoli, G. I., Hadlich, M., Barros, M. V. D. L., ... & Meirelles, V. (2011). Risk of coronary artery disease in individuals infected with human immunodeficiency virus. Brazilian Journal of Infectious Diseases, 15, 521-527.
Wang, X., Chai, H., Yao, Q., & Chen, C. (2007). Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. JAIDS Journal of Acquired Immune Deficiency Syndromes, 44(5), 493-499.
World Health Organization. (2016). Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. World Health Organization.
World Health Organization. (2016). Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis (No. WHO/HIV/2016.06). World Health Organization.
Worm, S. W., Sabin, C., Weber, R., Reiss, P., El-Sadr, W., Dabis, F., ... & Lundgren, J. (2010). Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D: A: D) study. The Journal of infectious diseases, 201(3), 318-330.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Ursula Maria Moreira Costa Burgos; Enaldo Vieira de Melo; Angela Maria da Silva; Antônio Carlos Sobral Sousa; Willams de Matos; Maria Aline Moura Reis; Lucas Alves Bezerra; Dalmo Correia Filho; Joselina Luzia Menezes Oliveira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
